Allogene Therapeutics, Inc.

The company did not provide revenue, EPS, gross margin, or cash figures in the transcript. For forward looking guidance, management kept the ALPHA3 interim EFS timing at roughly the previously guided mid-2027 window, said the study target remains 220 randomized patients, and now expects approximately 100 active sites by year-end, with the significant majority in the U.S. and additional sites in Canada, Australia, and South Korea. For RESOLUTION/ALLO-329, management said it expects a clinical and translational update in Q4 2026, and for ALPHA3 it expects opportunities in 2027 to update investors on enrollment progress and potential interim EFS data, subject to regulatory discussions and the DMC.

Zachary Roberts framed the quarter as the start of a new chapter and emphasized a strategy built around starting with the patient and designing allogeneic CAR-T to solve real-world access and logistics barriers. He repeatedly argued that allogeneic CAR-T is a distinct platform, not just a bridge to autologous therapy or other future modalities, and said the company is now seeing that thesis in ALPHA3, ALLO-316, and ALLO-329. His tone was confident and constructive, especially around ALPHA3, where he highlighted increasing investigator interest, regulatory validation, and progress toward broader community adoption.

Geoff Parker did not provide a detailed financial commentary in the prepared remarks on this transcript, and no quarterly income statement or balance sheet figures were stated. The only explicit financial-style operational guidance discussed was around program timing and scale: ALPHA3 remains targeted at 220 randomized patients, the EFS interim is still expected around mid-2027, and the company now expects about 100 active sites by year-end. No cash burn, runway, margin, or capital allocation numbers were given.

Analysts focused heavily on ALPHA3, asking about the new observational MRD-negative cohort, the possibility of earlier-than-guided interim EFS timing, the academic/community site mix, and whether enrollment could exceed the current 220-patient target. Management said the observational cohort is meant to provide context by pairing MRD-negative patients from a similar population to better characterize the test prospectively, kept the EFS timing unchanged despite faster site activation, said interest has been strong in both academic and community settings, and reiterated that 220 remains the target unless future data justify a change. Questions also centered on the RMAT/Fast Track decision and ALLO-329’s Q4 readout; management said the FDA package included the April MRD data plus a more extensive safety and MRD briefing, and for ALLO-329 it expects Q4 safety, efficacy, and translational data across the 20 million, 40 million, and 80 million dose cohorts.